24 May 2013
Keywords: tarceva, ph, ii, brain, cancer, study, starts
Article | 18 August 2003
Tarceva (erlotinib), under development with Genentech, Roche and OSI Pharmaceuticals, has entered Phase II evaluation as a potential
treatment for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 August 2003
© 2013 thepharmaletter.com